Milner Therapeutics Institute featured in AstraZeneca-University of Cambridge partnership impact report
The Milner Therapeutics Institute is delighted to be featured in a new report celebrating a decade of partnership and impact between AstraZeneca and the University of Cambridge.
Last year, we established a new functional genomics laboratory at the MTI, Cambridge Biomedical Campus, in partnership with AstraZeneca and the Medical Research Council. Part of the UK Human Functional Genomics Initiative, the lab is contributing to the UK’s ambition of having the most advanced genomic healthcare system in the world.
AstraZeneca is also part of the Milner Therapeutics Consortium – currently consisting of nine pharmaceutical companies and three academic institutions, University of Cambridge; The Babraham Institute; and the Wellcome Sanger Institute. The Consortium connects companies with academics across Cambridge, facilitating pre-clinical research collaborations to discover and validate new therapeutic targets, apply novel technologies and better understand disease mechanisms in advanced cellular models across multiple disease areas.
